Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis
Irruption of decitabine and azacitidine has led to profound changes in the upfront management of older acute myeloid leukaemia (AML). However, they have not been directly compared in a randomised clinical trial. In addition, there are no studies comparing the optimal treatment schedule of each drug...
Guardado en:
Autores principales: | Miriam Saiz-Rodríguez, Jorge Labrador, Beatriz Cuevas, David Martínez-Cuadrón, Verónica Campuzano, Raquel Alcaraz, Isabel Cano, Miguel A. Sanz, Pau Montesinos |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c2d01b7cf4a649cfac3c23bf43700bdb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
por: Briot T, et al.
Publicado: (2017) -
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
por: Ritchie EK
Publicado: (2012) -
The first case of acute myeloid leukaemia/myeloid sarcoma with cytokeratin expression on blasts diagnosed on urine specimen
por: Claire Comerford, et al.
Publicado: (2021) -
Adhesion Molecules Involved in Stem Cell Niche Retention During Normal Haematopoiesis and in Acute Myeloid Leukaemia
por: Julien M. P. Grenier, et al.
Publicado: (2021) -
Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine
por: Carlo Pescia, et al.
Publicado: (2021)